Sprint Nextel Corporation(NYSE:S) shares declined 0.54% to $5.50 in the pre-market hour. Chief Executive Officer at Sprint Nextel, Dan Hesse believes that the company is on its way to boost its profit in 2014 after facing losses during the last seven years. Hesse said that the Sprint has to cover a lot of distance but in 2014 the company’s profit-margin will expand and earnings will also boost.
Will Sprint Bounce Back To New Highs? Find Out Here
Yingli Green Energy Hold. Co. Ltd. (ADR)(NYSE:YGE), last week, announced that announced that one of its wholly-owned subsidiaries, Yingli Green Energy Australia Pty. Ltd. (Yingli Australia), has signed a Master Distributor Agreement (the Agreement) with Solar 360 Pty Ltd. (Solar 360) to appoint Solar 360 as a sales partner in Australia. According to the Agreement, Solar 360 will sell and promote 30 MW of Yingli Solar modules in Australia in the following 12 months through a unique Accredited dealer network of up to 100 accounts across all geographic regions of Australia.
WisdomTree DEFA Equity Income Fund (ETF)(NYSEARCA:DTH) 52 week trading range for the company is $33.11 - $41.53. The shares of the company gained 13% in the last one year. DTH seeks investment results that closely correspond to the price and yield performance of the WisdomTree DEFA Equity Income Index (the Index).
Ameriprise Financial, Inc.(NYSE:AMP) plans to host a live audio webcast of its third quarter 2012 investor conference call on Thursday, October 25, 2012 at 9:00 a.m. (ET). The company’s third quarter financial results are scheduled to be released on Wednesday, October 24, 2012 soon after the market closes.
Additionally, the company is in advanced talks to buy most of ING Group's (ING.AS) asset management business in Asia. The companies are still negotiating on price and an announcement may come in two to three weeks.
Get Free Trend Analysis On AMP Here
GlaxoSmithKline plc (ADR)(NYSE:GSK) shares fell 0.09% to $47.01 in pre-market hour after Glaxosmithkline Plc and Theravance, Inc. announced that the New Drug Application (NDA) for the once-daily investigational medicine fluticasone furoate FF/vilanterol VI (FF/VI) for patients with chronic obstructive pulmonary disease (COPD), has been accepted by the US Food and Drug Administration (FDA) indicating that the application is sufficiently complete to permit a substantive review.